Open AccessRole of Letrozole in Management of Female Infertility; Review Article
Author(s) -
Maha Fouad Messawa,
Salma Yousef Omar,
Reem Ahmed Babagi
Publication year - 2021
Publication title -
journal of pharmaceutical research international
Language(s) - English
Resource type - Journals
ISSN - 2456-9119
DOI - 10.9734/jpri/2021/v33i48a33249
Subject(s) - letrozole , infertility , ovarian hyperstimulation syndrome , controlled ovarian hyperstimulation , pregnancy rate , aromatase , medicine , aromatase inhibitor , gynecology , pregnancy , ovulation induction , obstetrics , in vitro fertilisation , biology , cancer , breast cancer , genetics
Background: Letrozole is a highly steroidal and selective oral aromatase inhibitor (AI). Serval studies shows that Co-treatment with letrozole significantly reduced gonadotropin consumption and the incidence of Ovarian Hyperstimulation Syndrome in normal/high responders, with pregnancy outcomes comparable to or better than the other groups. In this article we will be looking at role of letrozole in treatment of infertility
Methodology: A simple systematic review was carried out, searching databases PubMed, Google Scholar, and EBSCO. The authors extracted qualitative data, and then the author's names, year, study type, methodology, and the result were reported.
Results and Conclusion: Letrozole has effectiveness which is near the usage of the Human Menopausal Gonadotrophin in the numbers of pregnancies per cycle but have much less cost which indicates cost effectiveness of the drug. Furthermore, studies show that administration of the drug is effective in inducing pregnancy, with higher dose more than 5mg and 7.5mg more effective.